Immutep Advances IMP761 to Multiple Ascending Dose Phase After 14 mg/kg Dosing
Immutep completed the SAD portion of its first-in-human Phase I trial of IMP761, up to 14 mg/kg dosing, with no safety concerns or dose-limiting toxicities observed. The study has moved into the multiple ascending dose phase, targeting MAD completion in Q3 2026 with full Phase I data showcased on June 4.
1. Phase I SAD Completion
Immutep has successfully completed the single ascending dose portion of its first-in-human Phase I study of IMP761, administering doses up to 14 mg/kg. The treatment was well tolerated across all dose levels with no dose-limiting toxicities or safety concerns observed.
2. Progression to MAD Portion
The trial has advanced into the multiple ascending dose phase to evaluate pharmacokinetics and safety at two dosage levels. Completion of this MAD portion is anticipated in the third quarter of 2026, setting the stage for further clinical assessment.
3. Next Steps and Potential Applications
Full Phase I data, including immunosuppressive effects and tolerability profiles, will be presented on June 4 at the EULAR conference. Positive findings support progression to a potential Phase II trial targeting autoimmune diseases such as rheumatoid arthritis and type 1 diabetes.